Sarepta Therapeutics Announces Third Year of Route 79, The Duchenne Scholarship Program
February 27 2020 - 8:30AM
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision
genetic medicine for rare diseases, today announced that the
website for Route 79, The Duchenne Scholarship Program, is
officially open and accepting applications. Academic scholarships
of up to $5,000 will be awarded to up to 20 individuals chosen by
an independent committee of Duchenne community members based on an
applicant’s community involvement, personal essay and
recommendation letter. The Route 79 program is designed to help
students with Duchenne pursue their post-secondary educational
goals.
“Since launching Route 79, The Duchenne
Scholarship Program, two years ago, Sarepta has granted a total of
33 scholarships. In 2019 alone scholarship recipients hailed from
10 different states, representing 19 different academic
institutions, pursing degrees in the humanities, science and
technology, hospitality management, journalism, and business, among
others. It’s with great pride that we offer this scholarship for
the third consecutive year as a way to recognize and help bright,
hard-working individuals with Duchenne continue their educational
pursuits,” said Diane Berry, Sarepta’s Senior Vice President of
Global Health Policy, Government and Patient Affairs.
The underlying cause of Duchenne is a mutation
or error in the gene coding for dystrophin. Dystrophin is an
essential protein that plays a pivotal role in muscle structure,
function and preservation. The numerical significance of the
scholarship’s name, Route 79, ties to the 79 exons of the
dystrophin gene.
To apply for a scholarship through the Route 79
program, applicants must be accepted to or enrolled in an
accredited college or university or a trade, technical or
vocational school located in the United States and be diagnosed
with Duchenne muscular dystrophy. College seniors or college
graduates accepted to or enrolled in graduate school are also
eligible to apply. Previous recipients of Route 79, The Duchenne
Scholarship are eligible to apply for the 2020 Scholarship Program.
Acceptance into previous years of the Scholarship Program will have
no bearing on 2020 applications. No consideration will be given to
whether an applicant was previously, is currently, or expects to be
in the future, undergoing treatment with a Sarepta product or
investigational product.
Applications will be accepted until April 15,
2020, at 11:59 PM PT. Recipients will be notified in June and
awards will be distributed prior to August in time for fall 2020
enrollment. Students may apply by clicking here.
About Sarepta
TherapeuticsAt Sarepta, we are leading a revolution in
precision genetic medicine and every day is an opportunity to
change the lives of people living with rare disease. The Company
has built an impressive and competitive position in Duchenne
muscular dystrophy (DMD) and in gene therapies for limb-girdle
muscular dystrophies (LGMDs), mucopolysaccharidosis Type IIIA,
Charcot-Marie-Tooth (CMT), and other CNS-related disorders, with
more than 40 programs in various stages of development. The
Company’s programs and research focus span several therapeutic
modalities, including RNA, gene therapy and gene editing. For more
information, please visit www.sarepta.com or follow us on Twitter,
LinkedIn, Instagram and Facebook.
Internet Posting of
Information
We routinely post information that may be
important to investors in the 'For Investors' section of our
website at www.sarepta.com. We encourage investors and
potential investors to consult our website regularly for important
information about us.
Source: Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc.
Investors: Ian Estepan, 617-274-4052iestepan@sarepta.com
Media:Tracy Sorrentino,
617-301-8566tsorrentino@sarepta.com
Sarepta Therapeutics (NASDAQ:SRPT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sarepta Therapeutics (NASDAQ:SRPT)
Historical Stock Chart
From Apr 2023 to Apr 2024